Compare Novavax Inc (NVAX) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Ryanair Holdings plc — how do they compare? Novavax Inc trades at $9.88 (market cap $1.68B), while Ryanair Holdings plc trades at $54.19 (market cap $27.58B). The key difference: Ryanair Holdings plc is far larger — about 16.4× Novavax Inc's market cap, and Ryanair Holdings plc pays a 1.65% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | RYAAY | |
|---|---|---|
Market Cap | $1.68B | $27.58B |
Sector | Health | Industrials |
52-Week High | $11.19 | $73.82 |
52-Week Low | $6.22 | $53.24 |
Enterprise Value | $1.26B | $24.53B |
Dividend Yield | — | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
RYAAY trades at $54.37, down 1.79% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing strong revenue growth trends. Recent news highlights operational challenges including traffic outlook reductions and cost pressures from unhedged fuel. Cash flow remains positive from operations but net cash flow turned negative in 2025 and 2026 projections.
The outlook is cautious due to near-term headwinds from fuel costs and competitive pricing, but long-term fundamentals remain solid with attractive valuation multiples. Investment opportunity exists for value-oriented investors given low P/E of 13.09 and strong profitability metrics. Key risks include oil price volatility and winter capacity constraints affecting profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
